<DOC>
	<DOCNO>NCT02849639</DOCNO>
	<brief_summary>The study examine impact cognitive reserve pharmacist-physician patient-centered medication therapy management intervention address inappropriate medication use identify Beers 2015 list . By bolster cognitive reserve , project directly address National Alzheimer 's Project Act 2015 priority serve delay onset symptom preclinical dementia . The result study provide valuable insight expand intervention reduce prevalence associate healthcare cost symptomatic Alzheimer 's disease .</brief_summary>
	<brief_title>The INCREASE Study - Delaying Onset Alzheimer 's Symptomatic Expression</brief_title>
	<detailed_description>This 12-month , parallel arm , study conduct University Kentucky . The study involve assess medication use identify medicine may inappropriate elderly adult . At begin study , participant ask undergo one amyloid-PET scan detect early amyloid plaque brain could increase risk Alzheimer 's disease near future . In addition , begin end study , participant ask use scopolamine patch . This patch use prevent motion sickness ( approved FDA ) , instead use challenge participant 's memory thinking ability . Part study include collect information regard participant memory think ability . Participants ask complete questionnaire well memory think test . A study doctor review participant medical history perform routine medical ( physical neurological ) examination . Two study visit conduct phone check participant . At begin , middle , end study , participant meet doctor pharmacist review make change deem appropriate current medicine . This do order try eliminate medicine recommend elderly . These visit refer Medication Therapy Management ( MTM ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<criteria>Nondemented No previous reaction contraindication scopolamine patch , medical condition warrant dose adjustment scopolamine include limited : open angle glaucoma , gastrointestinal urinary outlet obstruction , seizure , psychosis . No contraindication AβPET scan include hypersensitivity PET ligand radiation exposure past year would exceed acceptable safe annual exposure combination Aβ PET Medically stable able complete study activity , determine investigator Reporting least one potentially inappropriate medication list Beers 2015 criterion Living community Willing participate intervention study Allergy know intolerance scopolamine patch Narrowangle glaucoma Difficulty swallow Stomach bowel problem ( e.g. , blockage , muscle weakness , ulcerative colitis ) Bleeding Acid reflux disease Myasthenia gravis Blockage urinary tract . Seizures Psychosis</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>101 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>